Apellis Pharmaceuticals, Inc.
APLS
$23.34
-$0.15-0.64%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 31.46% | 46.39% | 62.57% | 58.73% | 49.34% |
| Total Depreciation and Amortization | -1.91% | -0.44% | 0.73% | 7.67% | 11.99% |
| Total Amortization of Deferred Charges | 428.02% | 591.33% | 424.92% | 254.92% | 46.84% |
| Total Other Non-Cash Items | -17.96% | -12.80% | -5.34% | 2.19% | -20.03% |
| Change in Net Operating Assets | 157.23% | 135.66% | 90.83% | 44.94% | -57.75% |
| Cash from Operations | 101.10% | 98.49% | 85.23% | 67.83% | 34.46% |
| Capital Expenditure | 85.33% | 85.38% | 47.87% | 68.74% | 68.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 81.92% | 83.33% | 40.21% | -100.31% | -100.17% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -76.76% | -85.92% | -95.92% | -89.88% | -89.27% |
| Repurchase of Common Stock | 12.20% | 47.83% | 99.48% | 99.66% | 99.70% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 97.23% | -875.11% | -326.26% | -516.35% | -512.61% |
| Cash from Financing | -96.48% | -62.99% | -62.17% | -60.96% | -60.52% |
| Foreign Exchange rate Adjustments | -2.70% | 30.00% | -588.15% | 439.69% | 327.19% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 103.92% | 107.47% | 130.04% | 58.12% | -2,308.47% |